Female pattern hair loss, common in women, can be treated with various methods like minoxidil, anti-androgen treatments, and light therapy, but early intervention and realistic expectations are crucial.
September 2004 in “PubMed” Androgenetic alopecia, or hair loss, is influenced by hormones and genetics, and can be treated with medications like minoxidil, finasteride, or hormone therapy, with effectiveness evaluated after 6 months.
November 1999 in “Journal of Cutaneous Medicine and Surgery” Treatments for hair loss include hormone modifiers, minoxidil, and hair transplant surgery.
Women with androgenetic alopecia have normal levels of most blood steroids and binding proteins, but higher dehydroepiandrosterone. Some also have low "sex hormone-binding globulin" and "corticosteroide-binding globulin" capacity, and high "free androgen index" and "free cortisol index". Diane treatment can normalize these levels and improve hair conditions.
39 citations
,
May 2002 in “Oral Microbiology and Immunology” Testosterone increases cell growth and reduces IL-6 in gum cells.
9 citations
,
June 1999 in “Acta Obstetricia Et Gynecologica Scandinavica” Oral contraceptives are effective for treating hyperandrogenism, while ovarian electrocautery is better for women with infertility.
4 citations
,
January 1982 in “Endocrinologia Japonica” Androgens regulate 5 alpha-reductase activity in hamster sebaceous glands.
1 citations
,
November 2019 in “Archives of breast cancer” Some hormone treatments might raise breast cancer risk, while others don't seem to.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
2 citations
,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
164 citations
,
January 2003 in “Drugs”
16 citations
,
August 2004 in “Tetrahedron” Scientists made all eight versions of a compound called cyoctol, but found it's not an anti-androgen and it fully breaks down in the skin.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
January 2002 in “Chinese Journal of Pharmaceuticals” A new method was developed to make a compound used in finasteride and epristeride with a 69% yield.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.